GREAT POINT PARTNERS LLC
GREENWICH, CT · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$380.9M2026 Q3+ $37.5M options (notional, not included)
Positions45
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.49.5%
What Changed This Quarter?
Top Holdings
IBRXPUT
ImmunityBio
6.8%
VERA
Vera Therapeutics
6.2%
VOR
Vor Biopharma
5.1%
AMLX
Amylyx Pharmaceuticals
4.9%
SGMT
Sagimet Biosciences
4.6%
DFTX
Definium Therapeutics
4.6%
IONS
Ionis Pharmaceuticals
4.5%
GMAB
Genmab A/S
4.5%
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.